We invite you to join us for an informational presentation about the latest advances in treatment options for uterine fibroids.
Learn More(opens in a new tab)
Many women return to normal activity the next day.
The fibroids are treated from inside the uterus, so there’s no cutting or scarring.
Unlike a hysterectomy, treatment with the Sonata system does not eliminate the possibility of pregnancy.
For Nicole, Sonata means living the life she always wanted to live without having to think about her period
Advanced Women’s Health Institute is performing a study on eligibility for a new incisionless procedure for uterine fibroids called Sonata.
The Sonata Treatment is an incisionless treatment option for women with symptomatic uterine fibroids. It shrinks the fibroids and reduces bleeding with a short recovery period of 2-3 days.
To qualify for our study, you must:
To see if you qualify for Sonata, you will need to register and send ultrasound, CT or MRI reports and/or images regarding your uterine fibroids through our secure, HIPAA-compliant platform. You will be contacted about your eligibility with a summary report from the principal investigator.
To register, fill out our simple, secure online form. We look forward to helping you find relief!
Uterine fibroids are non - cancerous (benign) growths in or around the uterus. The vast majority of women in the United States will have fibroids by the age of 50.
The Sonata Treatment is an incisionless treatment option for women with symptomatic uterine fibroids. It is an outpatient procedure in the United States. The technical term for the procedure is Transcervical Fibroid Ablation (TFA).
The Sonata treatment device is inserted by the doctor through the vagina and into the uterus. Radiofrequency energy is delivered to the fibroid, causing it to shrink over time and relieve symptoms. The procedure typically takes less than one hour, depending on the number and size of fibroids treated. Learn more here: How Sonata Works
In a clinical study, 86% of women experienced a reduction in heavy menstrual bleeding within 3 months.
I would tell any woman who is thinking about getting a hysterectomy, to look into the Sonata process first.
I would tell a woman thinking about Sonata that you want to try this
Intended Use: The Sonata System is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
Contraindications: Current pregnancy; active pelvic infection; known or suspected gynecologic malignancy or premalignant disorders such as atypical endometrial hyperplasia; presence of one or more intratubal implants for sterilization; and presence of an intrauterine device (IUD), unless removed prior to the introduction of the Sonata Treatment Device.
Anticipated Postoperative Events: abdominopelvic pain/cramping; back pain; constipation; dizziness/fatigue; headache; fever; malaise; post-ablation inflammatory symptoms; nausea/vomiting; sloughing and, less commonly, intact expulsion of ablated fibroid tissue per vaginam (particularly after treatment of submucous fibroids), and vaginal spotting/bleeding/dysmenorrhea.
Potential Risks associated with fibroid ablation using the Sonata System include: allergic reactions (including rash) to device materials; bowel or bladder perforation; cervical/vaginal laceration or tear; dysmenorrhea; electrical shock; hematometrium; hemorrhage; infections: major and minor local and systemic infections, including intrauterine infection; retention of device fragment; skin burn from the dispersion of radiofrequency energy; thrombotic events; unintended injury to the uterus, cervix or vaginal vault, adjacent organs or tissue; unknown risk to future pregnancies; and complications including death.
Pregnancy: Safety and effectiveness with regard to fertility and fecundity after use of the Sonata System have not been established. As a uterus-conserving alternative to hysterectomy, treatment with the Sonata System does not eliminate the possibility of pregnancy.
Adenomyosis: Effectiveness in women with clinically significant adenomyosis has not been established.